|7 December 2016|
A pioneering digital-biotechnolgy company headquartered in Ireland has announced ambitious expansion plans for 2017.
The multi-award winning Nuritas uses artificial intelligence, deep learning and DNA analysis to ‘predict and provide access to the most health-benefiting components hidden within food called peptides that can manage and improve human health’.
Founded by mathematician and computational biologist, Dr Nora Khaldi, the company will triple its workforce in Ireland to over 60 in 2017 as part of a major expansion of its Irish operations.
The company also revealed U2 band members Bono and The Edge are investing in the company. The rock legends were recently at Nuritas’ offices in Dublin to mark the announcement of the Irish expansion as well as further growth of its US-based operations.
Today’s announcement comes on the back of Nuritas’ recent award of €3 million in European Union (EU) and associated funding to help bring to market a breakthrough food ingredient, labelled a potential world-first in diabetes prevention, with clinical trials set to get underway imminently.
Emmet Browne, CEO of Nuritas, said: “Growing up in Dublin watching U2 gain global impact and recognition, makes today a really special occasion as the Edge and Bono are now helping us on a similar journey. I’m thrilled to have them on board and they have already provided enormous support and enthusiasm, proactively connecting and opening doors to help our growth and expansion. Just as they started out performing in front of a small few and are now playing before a global audience of billions, we aim to do exactly the same with Nuritas.”
Nuritas Founder, Dr Nora Khaldi, added: “We aim high and think outside the box at Nuritas which is something that Bono and the Edge have done throughout their careers. We are delighted to have them join the Nuritas family and embrace our mission of improving the health of billions of people around the world.”